Telix Pharmaceuticals Financials
| TLPPF Stock | USD 16.00 0.82 5.40% |
Telix |
Telix Pharmaceuticals Stock Summary
Telix Pharmaceuticals competes with Sino Biopharmaceutica, Defence Therapeutics, Aileron Therapeutics, and Enlivex Therapeutics. Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 55 Flemington Road, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | telixpharma.com |
| Phone | 61 3 3093 3897 |
| Currency | USD - US Dollar |
Telix Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Telix Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Telix Pharmaceuticals reports annually and quarterly.Telix Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telix Pharmaceuticals competition to find correlations between indicators driving Telix Pharmaceuticals's intrinsic value. More Info.Telix Pharmaceuticals Limited is rated below average in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Telix Pharmaceuticals Systematic Risk
Telix Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Telix Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Telix Pharmaceuticals correlated with the market. If Beta is less than 0 Telix Pharmaceuticals generally moves in the opposite direction as compared to the market. If Telix Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Telix Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Telix Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Telix Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Telix Pharmaceuticals December 15, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Telix Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Telix Pharmaceuticals Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Telix Pharmaceuticals Limited based on widely used predictive technical indicators. In general, we focus on analyzing Telix Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Telix Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.18 | |||
| Information Ratio | 0.063 | |||
| Maximum Drawdown | 13.75 | |||
| Value At Risk | (5.03) | |||
| Potential Upside | 5.55 |
Complementary Tools for Telix Pink Sheet analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |